Concepedia

Sam Jackson

SJ

8

Publications

484

Citations

8

H-Index

2013

Active since

Affiliations

Dynavax Technologies (United States)(Current)

AstraZeneca (Sweden)

Stanford University

Sam Jackson is an author at Dynavax Technologies (United States) specializing in vaccinology, vaccination, and humoral immunity.

Top concepts

Publications per year

2013–2020

8

Publications

8

Immunogenicity of a two-dose investigational hepatitis B vaccine, HBsAg-1018, using a toll-like receptor 9 agonist adjuvant compared with a licensed hepatitis B vaccine in adults

Sam Jackson, Joseph R. Lentino, James Kopp et al. · Vaccine · 2017 · 185 citations · Full text

Safety, Tolerability, and Feasibility of Young Plasma Infusion in the Plasma for Alzheimer Symptom Amelioration Study

Sharon J. Sha, Gayle K. Deutsch, Lü Tian et al. · JAMA Neurology · 2018 · 108 citations · Full text

Safety of a two-dose investigational hepatitis B vaccine, HBsAg-1018, using a toll-like receptor 9 agonist adjuvant in adults

Randall N. Hyer, Darren K. McGuire, Biao Xing et al. · Vaccine · 2018 · 58 citations · Full text

Immunogenicity of an investigational hepatitis B vaccine with a toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared with a licensed hepatitis B vaccine in subpopulations of healthy adults 18–70 years of age

Julia M. Janssen, Sam Jackson, William L. Heyward et al. · Vaccine · 2015 · 44 citations

, , +11

First‐in‐Human Study With the Inhaled TLR9 Oligonucleotide Agonist AZD1419 Results in Interferon Responses in the Lung, and Is Safe and Well‐Tolerated

Sam Jackson, Albert F. Candia, Stephen Delaney et al. · Clinical Pharmacology & Therapeutics · 2017 · 29 citations

Rows per page

1–5 of 8